Pre-Cosmetic Sx Advice May Aid Long-Term Smoking Cessation

Share this content:
Pre-Cosmetic Sx Advice May Aid Long-Term Smoking Cessation
Pre-Cosmetic Sx Advice May Aid Long-Term Smoking Cessation

WEDNESDAY, Sept. 6, 2017 (HealthDay News) -- Asking patients to stop smoking before undergoing cosmetic surgery can promote long-term smoking cessation, according to a study published in the September issue of Plastic and Reconstructive Surgery.

Aaron C. Van Slyke, M.D., from the University of British Columbia in Canada, and colleagues conducted a retrospective cross-sectional cohort study involving 85 patients who smoked before their preoperative consultation, quit two weeks before surgery, and then underwent rhytidectomy, abdominoplasty, or mastopexy. At long-term follow-up, patients were asked to complete a survey; 47 patients completed the survey, with an average follow-up of 63.3 months.

Five of the respondents were social smokers and excluded. At long-term follow-up, the researchers found that 40.5 percent of the 42 daily smokers were no longer smoking cigarettes on a daily basis. Ten of these 17 patients had not smoked since their operation. Overall, 57.1 percent of patients had reduced their cigarette consumption by any amount, and 70.8 percent of these patients agreed that discussing adverse surgical outcomes associated with smoking influenced their ability to quit or reduce smoking. Half of the patients admitted that they were not compliant with the preoperative smoking cessation instructions.

"The authors have shown a positive association between smoking cessation and cosmetic surgery," the authors write. "Requesting a period of cessation before cosmetic surgery may promote long-lasting smoking cessation."

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »